Percheron Therapeutics is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the most difficult-to-treat cancers.
Dr Michael BakerMD & CEOPercheron Therapeutics
A welcome from our MD & CEO
Your dedicated resource for staying informed and engaged with our journey.
As we advance our lead asset, HMBD-002, for the treatment of various cancers, we are committed to keeping investors updated with the latest trial milestones, market insights, and corporate progress.
Visit our website for easy access to key announcements, reports, and to learn about opportunities to connect with our team.
We value your support and look forward to sharing our growth and success with you.
Thank you for being part of Percheron Therapeutics’ Journey.
Our commitment
At Percheron our commitment goes beyond the science of novel therapies, and we are determined to engage constructively with patients and advocacy organisations.
Compassionate Use and Expanded Access Policy
Share price
Current price
Volume
Market Cap.
Year low - high
Market data chart (ASX:PER)
Volume traded
Share price ()
Share price
Volume
Announcements
Last price
Open price
Day low - high
Price change
Percentage change
Previous close
Volume (no. of shares)
Turnover
Market cap
Shares outstanding
VWAP
Bid / Ask
52 week high
52 week low
Price/earnings ratio
Earnings per share
